A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Latest Information Update: 29 Jan 2025
Price :
$35 *
At a glance
- Drugs Troriluzole (Primary)
- Indications Obsessive-compulsive disorders
- Focus Registrational; Therapeutic Use
- Sponsors Biohaven Pharmaceuticals
- 09 Jan 2025 Planned End Date changed from 1 Dec 2024 to 1 Jun 2025.
- 09 Jan 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jun 2025.
- 29 May 2024 According to Biohaven Therapeutics media release, company expects interim data analysis from second ongoing Phase 3 OCD trial in 4Q2024.